This is a preview of subscription content, log in via an institution to check access.
References
1. Delea TE, et al. Cost-Effectiveness of Blinatumomab Versus Chemotherapy in Adult Patients with Acute Lymphoblastic Leukemia in First Hematological Complete Remission with Minimal Residual Disease Using a Markov Cohort Approach. 25th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research : (plus poster) abstr. N/A, 18 May 2020. Available from: URL: https://www.ispor.org/heor-resources/presentations-database/presentation/intl2020-3182/102489
2. Delea TE, et al. Comparison of Partitioned Survival Versus Markov Cohort Modeling Approaches in the Evaluation of Cost-Effectiveness of Blinatumomab Versus Chemotherapy in Adult Patients with Acute Lymphoblastic Leukemia in First Hematological Complete Remi ... 25th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research : (plus poster) abstr. N/A, 18 May 2020. Available from: URL: https://www.ispor.org/heor-resources/presentations-database/presentation/intl2020-3182/102496
3. Delea TE, et al. Cost-Effectiveness of Blinatumomab Versus Standard of Care in Adult Patients with Philadelphia-Chromosome-Positive Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia from a Canadian Healthcare Sector Perspective. 25th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research : (plus poster) abstr. N/A, 18 May 2020. Available from: URL: https://www.ispor.org/heor-resources/presentations-database/presentation/intl2020-3182/102315
4. Tanaka S, et al. Cost by Outcomes Analysis of Blinatumomab and Inotuzumab Ozogamicin for Acute Lymphoblastic Leukemia from the Brazilian Private Healthcare Perspective. 25th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research : (plus poster) abstr. N/A, 18 May 2020. Available from: URL: https://www.ispor.org/heor-resources/presentations-database/presentation/intl2020-3182/100769
Rights and permissions
About this article
Cite this article
Cost effectiveness of blinatumomab for relapsed or refractory ALL highlighted at ISPOR. PharmacoEcon Outcomes News 855, 7–8 (2020). https://doi.org/10.1007/s40274-020-6872-8
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-020-6872-8